Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives.
Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives.
复制标题
DOI：
10.1155/2017/8013575
复制
发表时间：
2017
影响因子：
--
通讯作者：
Kaspera W
中科院分区：
文献类型：
--
作者：
Szopa W;Burley TA;Kramer-Marek G;Kaspera W
胶质母细胞瘤（GBM）是中枢神经系统的原发性神经上皮肿瘤，其特征在于极其侵袭性的临床表型。GBM患者预后差，只有3-5%的患者存活超过5年。目前的GBM治疗标准包括最大限度切除，然后进行放射治疗以及伴随和辅助治疗。尽管有这些积极的治疗方案，大多数患者由于GBM的分子异质性而复发。因此，已经研究了许多潜在的诊断、预后和预测生物标志物。其中一些，如IDH突变，1 p19 q缺失，MGMT启动子甲基化和EGFRvIII扩增在常规临床实践中经常进行测试。随着测序技术的发展，GBM分子特征的详细表征促进了更个性化的治疗方法，并有助于开发新一代抗GBM疗法，例如靶向生长因子受体的分子抑制剂、疫苗、基于抗体的药物缀合物以及最近阻断免疫检查点的抑制剂。在这篇文章中，我们回顾了令人兴奋的进展，阐明了当前和新的GBM生物标志物的潜力，并讨论了它们对临床实践的影响。
Glioblastoma (GBM) is a primary neuroepithelial tumor of the central nervous system, characterized by an extremely aggressive clinical phenotype. Patients with GBM have a poor prognosis and only 3–5% of them survive for more than 5 years. The current GBM treatment standards include maximal resection followed by radiotherapy with concomitant and adjuvant therapies. Despite these aggressive therapeutic regimens, the majority of patients suffer recurrence due to molecular heterogeneity of GBM. Consequently, a number of potential diagnostic, prognostic, and predictive biomarkers have been investigated. Some of them, such as IDH mutations, 1p19q deletion, MGMT promoter methylation, and EGFRvIII amplification are frequently tested in routine clinical practice. With the development of sequencing technology, detailed characterization of GBM molecular signatures has facilitated a more personalized therapeutic approach and contributed to the development of a new generation of anti-GBM therapies such as molecular inhibitors targeting growth factor receptors, vaccines, antibody-based drug conjugates, and more recently inhibitors blocking the immune checkpoints. In this article, we review the exciting progress towards elucidating the potential of current and novel GBM biomarkers and discuss their implications for clinical practice.